A detailed history of Trustmark National Bank Trust Department transactions in Abb Vie Inc. stock. As of the latest transaction made, Trustmark National Bank Trust Department holds 42,442 shares of ABBV stock, worth $7.81 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
42,442
Previous 48,445 12.39%
Holding current value
$7.81 Million
Previous $8.31 Million 0.87%
% of portfolio
0.63%
Previous 0.67%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$163.84 - $199.33 $983,531 - $1.2 Million
-6,003 Reduced 12.39%
42,442 $8.38 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $239,924 - $280,178
-1,550 Reduced 3.1%
48,445 $8.31 Million
Q1 2024

May 10, 2024

BUY
$159.82 - $182.1 $1.03 Million - $1.17 Million
6,433 Added 14.77%
49,995 $9.1 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $10,044 - $11,312
-73 Reduced 0.17%
43,562 $6.75 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $180,212 - $208,622
-1,349 Reduced 3.0%
43,635 $6.5 Million
Q2 2023

Aug 10, 2023

SELL
$132.51 - $164.9 $755,572 - $940,259
-5,702 Reduced 11.25%
44,984 $6.06 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $1,156 - $1,332
-8 Reduced 0.02%
50,686 $8.08 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $15,075 - $18,079
-109 Reduced 0.21%
50,694 $8.2 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $120,520 - $138,229
-898 Reduced 1.74%
50,803 $6.82 Million
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $360,702 - $458,570
2,621 Added 5.34%
51,701 $7.92 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $711,636 - $882,940
-5,392 Reduced 9.9%
49,080 $7.96 Million
Q4 2021

Feb 11, 2022

SELL
$107.43 - $135.93 $102,058 - $129,133
-950 Reduced 1.71%
54,472 $7.38 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $126,084 - $143,124
1,185 Added 2.18%
55,422 $5.98 Million
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $239,352 - $266,652
2,275 Added 4.38%
54,237 $6.11 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $415,235 - $457,124
4,059 Added 8.47%
51,962 $5.62 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $514,894 - $695,161
-6,397 Reduced 11.78%
47,903 $5.13 Million
Q3 2020

Nov 13, 2020

BUY
$85.91 - $100.83 $558,586 - $655,596
6,502 Added 13.6%
54,300 $4.76 Million
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $226,639 - $303,278
3,089 Added 6.91%
47,798 $4.69 Million
Q1 2020

May 14, 2020

BUY
$64.5 - $97.79 $67,725 - $102,679
1,050 Added 2.41%
44,709 $3.41 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $162,292 - $203,062
2,250 Added 5.43%
43,659 $3.87 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $11,336 - $13,629
-180 Reduced 0.43%
41,409 $3.14 Million
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $54,531 - $69,703
-830 Reduced 1.96%
41,589 $3.02 Million
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $44,741 - $52,658
-580 Reduced 1.35%
42,419 $3.42 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $256,904 - $316,833
3,300 Added 8.31%
42,999 $3.96 Million
Q3 2018

Feb 22, 2019

SELL
$88.91 - $98.84 $1.8 Million - $2 Million
-20,247 Reduced 33.78%
39,699 $3.75 Million
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $1.66 Million - $1.84 Million
18,651 Added 45.17%
59,946 $5.67 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $306,957 - $363,200
-3,419 Reduced 7.65%
41,295 $3.83 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $70,295 - $94,132
764 Added 1.74%
44,714 $4.23 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $321,072 - $352,082
-3,585 Reduced 7.54%
43,950 $4.25 Million
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $3.32 Million - $4.24 Million
47,535
47,535 $4.22 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $325B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Trustmark National Bank Trust Department Portfolio

Follow Trustmark National Bank Trust Department and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trustmark National Bank Trust Department, based on Form 13F filings with the SEC.

News

Stay updated on Trustmark National Bank Trust Department with notifications on news.